Visterra, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 2007-01-01
- Employees
- 51
- Market Cap
- -
- Website
- http://www.visterrainc.com
A Study to Evaluate Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Multiple Doses of VIS954
- First Posted Date
- 2025-04-22
- Last Posted Date
- 2025-04-22
- Lead Sponsor
- Visterra, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT06937593
- Locations
- 🇺🇸
Anaheim Clinical Trials, LLC, Anaheim, California, United States
A Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of VIS954 in Healthy Adult Participants
Phase 1
Active, not recruiting
- Conditions
- Healthy Volunteers
- Interventions
- Other: Placebo
- First Posted Date
- 2024-01-19
- Last Posted Date
- 2024-05-30
- Lead Sponsor
- Visterra, Inc.
- Target Recruit Count
- 54
- Registration Number
- NCT06212804
- Locations
- 🇺🇸
Visterra Clinical Site, Anaheim, California, United States
A Study to Evaluate the Safety, PK and PD of VIS171 in Participants (Healthy and with Autoimmune Disease)
- First Posted Date
- 2022-06-14
- Last Posted Date
- 2025-02-14
- Lead Sponsor
- Visterra, Inc.
- Target Recruit Count
- 61
- Registration Number
- NCT05418101
- Locations
- 🇲🇩
Clinical republican Hospital, Chisinau, Moldova, Republic of
🇧🇬Diagnostic and Consultative Center Convex EOOD, Sofia, Bulgaria
🇳🇱Radboud University Medical Center, Gelderland, Netherlands
Safety and Efficacy Study of VIS649 for IgA Nephropathy
Phase 2
Completed
- Conditions
- Immunoglobulin A NephropathyGlomerular DiseaseIgAN
- Interventions
- Drug: Medium Dose-VIS649Drug: High Dose-VIS649Drug: Dose-PlaceboDrug: Low Dose-VIS649
- First Posted Date
- 2020-02-27
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- Visterra, Inc.
- Target Recruit Count
- 155
- Registration Number
- NCT04287985
- Locations
- 🇬🇧
Visterra Investigational Site, Salford, United Kingdom
First in Human Study to Assess Safety of VIS649 in Healthy Subjects
Phase 1
Completed
- Conditions
- IgAN - IgA NephropathyIgA NephropathyImmunoglobulin A Nephropathy
- Interventions
- Biological: Placebo
- First Posted Date
- 2018-10-25
- Last Posted Date
- 2025-03-20
- Lead Sponsor
- Visterra, Inc.
- Target Recruit Count
- 51
- Registration Number
- NCT03719443
- Locations
- 🇺🇸
California Clinical Trials Medical Group, Glendale, California, United States
Study of Efficacy and Safety of IV VIS410 Plus Oseltamivir Versus Oseltamivir in Hospitalized Adults With Influenza A
Phase 2
Completed
- Conditions
- Influenza A
- Interventions
- Drug: Low dose of VIS410Drug: High dose of VIS410Drug: Placebo
- First Posted Date
- 2017-02-02
- Last Posted Date
- 2022-12-28
- Lead Sponsor
- Visterra, Inc.
- Target Recruit Count
- 89
- Registration Number
- NCT03040141
- Locations
- 🇺🇦
Visterra, Zhytomyr, Ukraine
Study of an Investigational Monoclonal Antibody, VIS410, in Subjects With Uncomplicated Influenza A
Phase 2
Completed
- Conditions
- Influenza
- Interventions
- Drug: VIS410 low doseDrug: PlaceboDrug: VIS410 high dose
- First Posted Date
- 2016-12-12
- Last Posted Date
- 2022-08-15
- Lead Sponsor
- Visterra, Inc.
- Target Recruit Count
- 150
- Registration Number
- NCT02989194
Influenza Challenge Study of VIS410 in Healthy Volunteers
- First Posted Date
- 2015-06-10
- Last Posted Date
- 2016-04-05
- Lead Sponsor
- Visterra, Inc.
- Target Recruit Count
- 46
- Registration Number
- NCT02468115
- Locations
- 🇧🇪
SGS Life Sciences, Antwerp, Belgium
A Study of VIS410 to Assess Safety and Pharmacokinetics
- First Posted Date
- 2014-01-24
- Last Posted Date
- 2015-05-14
- Lead Sponsor
- Visterra, Inc.
- Target Recruit Count
- 41
- Registration Number
- NCT02045472
- Locations
- 🇺🇸
DaVita Clinical Research, Minneapolis, Minnesota, United States
© Copyright 2025. All Rights Reserved by MedPath